• Parasites, Hosts and Diseases
• /
• 제33권2호
• /
• pp.131-134
• /
• 1995

톡소포자충의 증식형 (tachyzoite)인 RH주를 특정 무균 마우스(specific pathogen free mouse)의 대퇴부 근육에 주입하면 복강내 계대시 보다 1-2일 더 오래 생존한다 감염 경과에 따른 서혜부 림프절의 조직병리학적 변화를 관찰하기 위하여 근육내 주입후 1일. 3일 및 5일에 동측(동측) 서혜부 림프절과 반대편 서혜부 림프절을 얻어 hematoxylin-rosin으로 염색하였다. 주입후 1-3일의 동측 림프절 조직은 피질(cortex)과 부피질(paracortex) 영역에서 배중심(verminal center)의 발달 동 (sinus)의 팽창 및 유강피세포괴(cluster of epithelioid cells)의 발달 등이 관찰되었다. 주입후 5일 째의 동측 림프절에서는 림프절 구조가 대부분 사라지고. 세포수가 감소되었을 뿐만 아니라 국소 괴사가 관찰되었다. 이 실험에서 관찰한 괴사성 림프절염은 톡소포자충에 의한 림프절염에서 기록 되지 않았던 소견으로서 사람의 괴사성 림프절염과 톡소포자충과의 원인적 관계를 시사한다.

• Investigative Magnetic Resonance Imaging
• /
• 제17권1호
• /
• pp.59-62
• /
• 2013

이물질에 의한 주변조직의 반응성 변화는 염증, 부종, 액체저류, 혈종, 감염, 농양, 육아종 등의 다양한 형태를 보이며, 이물질의 종류와 시간 경과에 따라 다양한 영상소견을 보이기 때문에 연부조직 종양 등과 쉽게 혼동 할 수 있다. 자기공명 영상은 이물질의 방사선 투과성이나 음향 임피던스와 관계없이 진단할 수 있으며, 특히 주변조직의 변화를 잘 보여준다. 이에 저자들은 알약 분쇄물을 식염수와 섞어 전완에 주사한 후 발생한 종창으로 내원한 26세 여자의 자기공명 영상에서 무수히 많은 미세한 신호 강도 소실 물질과 주변의 액체저류 및 T1 저신호, T2 고신호 강도의 비균질성 조영증강 병변을 확인하였다. 이는 수술을 시행하여 흡수되지 않은 알약 분쇄물 및 주변의 액체저류와 염증반응으로 확인되었기에 이를 자기공명 영상소견과 함께 보고하고자 한다.

• 대한미생물학회지
• /
• 제20권1호
• /
• pp.115-125
• /
• 1985

Hemorrhagic fever with renal syndrome (HFRS) is a debilitating disease of humans caused by Hantaan virus (HV), the prototype member of a newly proposed genus of Bunyaviridae. Studies of HV pathogenesis have been limited by the absence of a well defined model for a virus-induced disease state. In an attempt to devise a model for HV pathogenesis in laboratory rodents, newborn outbred suckling ICR mice were shown to be uniformly susceptible to lethal infection with non- mouse adapted HV by intracerebral (IC), intraperitoneal (IP), intramuscular (IM), and subcutaneous (SC) inoculation routes. Clinical coures, mean time to death, and fatal outcome were age-dependent. With an inoculum of 10 $LD_{50}$, mortality was 100% in mice infected within 72h of birth, but declined to 50% by 7 days. By 2-2.5 weeks, animals developed complete resistance to clinical disease. Virus was consistently detected in serum by day 6 post-infection in IC- and IP- inoculated animals, and reached peak levels of $10^5\;PFU/ml$ by day 8 Mice infected IM and SC showed delays in onset of viremia, but achieved similar titers. Immunofluorescent antibody appeared by 17-18 days, and neutralizing antibody by 15 days, in all experimental groups. Two of 8 inbred mouse strains were identified as resistant to clinical disease : SJL/J and A/J. Manipulation of this model will allow investigation of natural rodent pathogenesis with HV, as well as offer insight into disease mechanisms and therapy of HFRS.

• Journal of Microbiology and Biotechnology
• /
• 제24권12호
• /
• pp.1728-1735
• /
• 2014

Scrub typhus, caused by infection with Orientia tsutsugamushi, is a mite-borne zoonotic disease endemic to the Asian-Pacific region. In Korea, the incidence of this disease has increased with climate changes, and over 10,000 cases of infection were reported in 2013. Although this infection is treatable with antibiotics such as doxycycline and azithromycin, an effective prophylactic vaccine against O. tsutsugamushi would be more desirable for preventing scrub typhus in endemic areas. In this study, we investigated the 56-kDa type-specific antigen (TSA56), which is a major outer membrane protein of O. tsutsugamushi, as a vaccine candidate. Intranasal immunization of recombinant TSA56 (rec56) induced a higher level of TSA56-specific IgG than that induced by intramuscular immunization of tsa56-expressing DNA (p56). Both types of immunization induced a cell-mediated immune response to TSA56, as demonstrated by the splenic cell proliferation assay. Mice immunized with p56, followed by rec56 plus heat-labile enterotoxin B subunit from E. coli, had a stronger protection from a homologous challenge with the O. tsutsugamushi Boryong strain than with other combinations. Our preliminary results suggest that an effective human vaccine for scrub typhus can include either recombinant TSA56 protein or tsa56-expressing DNA, and provide the basis for further studies to optimize vaccine performance using additional antigens or different adjuvants.

• 한국응용곤충학회지
• /
• 제58권4호
• /
• pp.283-289
• /
• 2019

항생제의 오남용은 세균의 항생제 내성을 증가시켜 세균감염에 의한 질병 치료에 어려움을 초래한다. 본 연구에서는 동애등애유충으로부터 분리된 펩타이드의 신장에서의 폐렴간균 감염 억제 효능을 관찰하였다. 마우스는 비강을 통해 폐렴간균을 감염시키고 1일 후 펩타이드를 마우스에 근육 주사로 투여하였다. 10일 후 마우스를 희생하여 신장에서 세균 감염증을 조사하였다. 대조군에 비해 펩티드를 투여한 마우스의 신장에서 세균 감염증상, 몸무게의 감소가 유의하게 억제되었고 생존률이 농도 의존적으로 증가하는 것으로 나타났다. 이러한 결과들은 동애등애로부터 분리된 펩타이드가 폐렴 간균의 신장에서의 감염증상을 억제할 수 있음을 보여준다. 따라서 동애등애로부터 분리된 펩타이드는 효과적인 항생제 개발에서 가능성 높은 후보물질이 될 수 있을 것이다.

• 병원약사회지
• /
• 제35권4호
• /
• pp.400-408
• /
• 2018

Background : Palivizumab is an intravenous monoclonal antibody which is used in the prevention of respiratory syncytial virus (RSV) infection. It is currently recommended for infants who are at high-risk for RSV infections due to preterm birth or other medical conditions such as congenital heart disease. Palivizumab is a humanized monoclonal antibody directed against an epitope in the antigenic site A of the protein F of RSV particles. Palivizumab is given once a month via intramuscular (IM) injection throughout the duration of the RSV season. Since palivizumab is known to have preventive effects against RSV infection for children with older siblings, the insurance coverage for palivizumab was expanded in October 2016. Methods : The electronic medical records of children under 2 years old who have older siblings who visited or were admitted to the Severance Hospital from October 2015 to May 2016 and from October 2016 to May 2017 were reviewed retrospectively. The data were then divided into two groups depending on the pilivizumab administration. Results : A total of 67 patients were enrolled in this study. The effectiveness in the reduction of hospitalization was statistically significant (p=0.009). Palivizumab decreased respiratory symptoms such as cough, rhinorrhea, and fever in patients with older siblings (p 0.05). Conclusions : In this study, palivizumab administration was effective in preventing RSV infection in infants with older siblings. Expanding palivizumab-prophylaxis administration to infants with older siblings may be effective in the prevention of upper respiratory infections.

• Toxicological Research
• /
• 제19권1호
• /
• pp.13-19
• /
• 2003

GX-12 is a naked DNA vaccine developed by the DongA Pharmaceutical Co. Ltd. and Genexine for the treatment of HIV infection. This study was peformed to evaluate the biodistribution and expression of GX-12 mRNA in gonadal tissues, and to investigate the histopathological changes after the repeated intramuscular injection. GX-12 (400 $\mu\textrm{g}$/head) was injected into the left anterior tibialis once a week for four weeks. On day 1, 5, 15, 30 and 45 after the final administration, gonadal tissues (testes, epididymis, seminal vesicles, penis, prostate glands, ovaries, vagina, uterus) and the injection site (muscle) were harvested and examined for the expression of mRNA by RT-PCR. In addition, histopathological examination was peformed at each time point. At the injection site, mRNA expression of GX-12 was detected only at early time points (1 ~ 15 days after injection) but not thereafter. However, in gonadal tissues, mRNA expression was not identified at all time points both in male and female rats. There were no histopathological changes in all reproductive organs and muscle. Based on these results, it is unlikely that the plasmid DNAs of GX-12 was distributed to- and expressed in gonadal tissues, suggesting that the chance of germline integration and transmission is negligible.

• 한국독성학회:학술대회논문집
• /
• 한국독성학회 2002년도 Molecular and Cellular Response to Toxic Substances
• /
• pp.199-200
• /
• 2002

GX-12 is a naked DNA vaccine developed by research team of Dong-A Pharmaceutical Company, Green Cross Company and Genexine for the treatment of HIV infection. It consists of four separate plasmids (pGX10-GE HX, pGX10-dpol JR, pGX10-VN/TV JR, pGX10-hIL-12m), which were constructed by inserting the HIV-1 gag-env, pol, regulatory genes and a human IL-12 mutant gene into pGX10 plasmid vectors.(omitted)

• 한국어병학회지
• /
• 제23권3호
• /
• pp.273-280
• /
• 2010

To determine whether rock bream Oplegnathus fasciatus can be protected from rock bream iridovirus (RBIV) infection by intramuscular injection of long double-stranded RNAs (dsRNAs), we compared protective effect of virus-specific dsRNAs corresponding to major capsid protein (MCP), ORF 084, ORF 086 genes, and virus non-specific green fluorescent protein (GFP) gene. Furthermore, to determine whether the non-specific type I interferon (IFN) response was associated with protective effect, we estimated the activation of type I IFN response in fish using expression level of IFN inducible Mx gene as a marker. As a result, mortality of fish injected with dsRNAs and challenged with RBIV was delayed for a few days when comparing with PBS injected control group. However, virus-specific dsRNA injected groups exhibited no significant differences in survival period when compared to the GFP dsRNA injected group. Semi-quantitative analysis indicated that the degree of antiviral response via type I IFN response is supposedly equal among dsRNA injected fish. These results suggest that type I IFN response rather than sequence-specific RNA interference might involve in the lengthened survival period of fish injected with virus-specific dsRNAs.

• 한국어병학회지
• /
• 제2권1호
• /
• pp.19-30
• /
• 1989

양식어류(養殖魚類)의 건강평가기준(健康評價基準)을 위한 기초자료(基礎資料)를 확보하고자 저자(著者)등은 1988년(年) 6월(月) 부터 1989년(年) 5월(月)까지 이스라엘잉어를 이용한 일련의 혈액조사(血液調査)를 실시하여 다음과 같은 결과(結果)를 얻었다. 1. 건강(健康)한 이스라엘잉어의 혈액상(血液像)은 Hct $32{\pm}3.4%$, Hb $8.3{\pm}0.9g/dl$, RBCs $132{\times}10^4{\pm}27.6{\times}10^4mm^3$, 총단백(總蛋白) $2.7{\pm}0.7g/dl$, GOT $143{\pm}19.5units$, GPT $50{\pm}14.2units$, 총혈당 $70{\pm}12.6mg/dl$, BUN $7.5{\pm}1.9mg/dl$ 등이었다. 2. 온수의 변화(變化)에 따른 혈액상(血液像)은 $23^{\circ}C$를 대조군(對照群)으로하여 $5^{\circ}C$ 하강(下降)시($18^{\circ}C$) Hct 및 RBCs수(數)가 감소(減少)하였으며, $5^{\circ}C$ 상승(上昇)시($28^{\circ}C$) Hct, RBCs수(數) 및 glucose량(量)이 증가(增加)하였다. 3. 용존산소량(溶存酸素量)의 변화(變化)에 따른 혈액상(血液像)은 4.5ppm을 대조군으로 하여 용존산소 감소(減少)시(3ppm) Hct 및 RBCs수가 증가(增加) 하였으며 용존산소 증가(增加)시(7ppm) Hct 및 RBCs수가 감소 하였다. 4. 연쇄구균(連鎖球菌) $10^6cells$/fish를 근육(筋肉)에 접종(接種)한 경우 염증성(炎症性) 반응(反應)과 함께 Hct, RBCs, glucose, BUN치(値)가 현저(顯著)히 감소(減少) 하였으며 이들은 6 일(日)만에 회복 되었다. 5. 연쇄구균 $10^4cells$/fish를 복강내(腹腔內)에 접종한 경우 역시 염증성 반응과 함께 Hct, RBCs, BUN치(値)가 감소 되었으나, 이 경우 폐사(斃死)된 예(例)는 없었다. 6. Edwardsiella tarda균 $1.2{\times}10^8cells$/fish를 근육(筋肉)에 접종한 경우 Hct 및 RBCs치(値)는 감소하였고, TCHO, GOT, GPT, BUN치(値)는 증가 하였으며, 격심(激甚)한 염증성(炎症性) 반응(反應)과 함께 접종 3~4일(日) 내(內)에 접종어(接種魚)의 60%가 폐사(斃死)하였다.